Abstract
The main treatment goal for postmenopausal women with advanced breast cancer who fail tamoxifen therapy is palliation, using further endocrine therapy to block tumour growth and reduce symptoms. Until recently, standard second-line therapy has been with a progestin (megestrol or medroxyprogesterone) or a non-specific aromatase inhibitor (aminoglutethimide). Two papers presented at the European Cancer Conference (ECCO) ’97 [Hamburg, Germany; September 1997], and data discussed in symposia, showed that 2 of the newer aromatase inhibitors, letrozole [‘Femara’, Novartis] and anastrozole [‘Arimidex’, Zeneca], were superior in various comparisons to megestrol and that letrozole was superior to aminoglutethimide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
